Checkpoint Therapeutics (NASDAQ:CKPT) Given “Neutral” Rating at HC Wainwright

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “neutral” rating restated by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $4.10 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 3.02% from the stock’s current price.

Other research analysts also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $4.80 price objective (down previously from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday.

Checkpoint Therapeutics Stock Up 61.1 %

NASDAQ CKPT opened at $3.98 on Tuesday. The company has a market cap of $194.36 million, a price-to-earnings ratio of -2.16 and a beta of 1.41. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The business’s fifty day moving average is $3.10 and its 200 day moving average is $3.08.

Insider Activity at Checkpoint Therapeutics

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. This represents a 20.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the sale, the chief executive officer now owns 3,194,583 shares of the company’s stock, valued at $10,797,690.54. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 582,336 shares of company stock worth $2,156,801 over the last quarter. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of institutional investors have recently modified their holdings of CKPT. Walleye Capital LLC acquired a new position in Checkpoint Therapeutics during the third quarter worth $148,000. State Street Corp raised its holdings in shares of Checkpoint Therapeutics by 32.2% in the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after acquiring an additional 23,000 shares during the last quarter. Geode Capital Management LLC lifted its position in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares in the last quarter. Virtu Financial LLC bought a new position in Checkpoint Therapeutics in the 3rd quarter valued at about $30,000. Finally, PVG Asset Management Corp boosted its stake in Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after purchasing an additional 12,676 shares during the last quarter. 22.00% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.